Bull Street Advisors LLC Sells 980 Shares of Pfizer Inc. (NYSE:PFE)

Bull Street Advisors LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 53,427 shares of the biopharmaceutical company’s stock after selling 980 shares during the quarter. Bull Street Advisors LLC’s holdings in Pfizer were worth $1,354,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Beam Wealth Advisors Inc. lifted its holdings in Pfizer by 1.5% in the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after purchasing an additional 401 shares during the last quarter. Providence Capital Advisors LLC lifted its stake in shares of Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after buying an additional 409 shares during the last quarter. Donaldson Capital Management LLC lifted its stake in shares of Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after buying an additional 410 shares during the last quarter. Noesis Capital Mangement Corp grew its stake in Pfizer by 2.6% in the 4th quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 413 shares during the last quarter. Finally, First Command Advisory Services Inc. grew its stake in Pfizer by 2.5% in the 4th quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 418 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on PFE shares. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Trading Up 0.2%

Shares of Pfizer stock opened at $24.30 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The firm has a 50-day moving average of $23.42 and a 200-day moving average of $24.85. The stock has a market cap of $138.18 billion, a PE ratio of 17.61, a PEG ratio of 0.88 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. During the same quarter in the prior year, the firm posted $0.82 EPS. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.08%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.